MRKR
Marker Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
Revenue Plunges
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MRKR
Marker Therapeutics, Inc.
A clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for hematological malignancies and solid tumor indications
Biological Technology
Invalid Date
11/08/2016
NASDAQ Stock Exchange
5
12-31
Common stock
9350 Kirby Drive, Suite 300, Houston, Texas 77054
--
Marker Therapeutics, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T-cell immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of unengineered tumor-specific T cells, which recognize tumor-associated antigens (i.e., tumor targets) and kill tumor cells expressing these targets. Once transfused into the patient, this group of T cells attacks multiple tumor targets and acts to activate the patient's immune system to generate broad-spectrum anti-tumor activity. Since Marker does not genetically engineer its T cells, its products are (i) less expensive, easier to manufacture, (ii) significantly less toxic, and (iii) associated with meaningful clinical benefits compared to current CAR-T and TCR-based engineering methods. Therefore, Marker believes that its T-cell therapy portfolio has a compelling therapeutic product profile compared to current genetically modified CAR-T and TCR-based therapies.
Company Financials
EPS
MRKR has released its 2024 Q4 earnings. EPS was reported at -0.41, versus the expected -0.22, missing expectations. The chart below visualizes how MRKR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRKR has released its 2024 Q4 earnings report, with revenue of 2.25M, reflecting a YoY change of 113.13%, and net profit of -3.84M, showing a YoY change of -36.91%. The Sankey diagram below clearly presents MRKR’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available